AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE at the International Conference on Alzheimer's and Parkinson's Diseases
|Program and Collaborator||Presentations and Timing|
| Crenezumab / |
| anti-Tau antibody / |
| Tau-PET imaging agent / |
|alpha-syn-PET imaging agent / Biogen|| |
|Morphomer Tau|| |
| Tau spreading / |
École Polytechnique Fédérale de Lausanne (EPFL)
| Abeta and Tau molecular profiling / |
Nestlé Institute of Health Sciences (NIHS)
Selected presentations and posters will be made available at the conclusion of the AD/PDTM 2017 Conference on AC Immune's website under the section Science.
Forward looking statements
This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
For further information please contact:
| Prof. Andrea Pfeifer |
Chief Executive Officer
Phone: +41 21 345 91 21
| Eva Schier |
Corporate Communications Manager
Phone: +41 21 345 91 34
Mobile: +41 79 926 66 03
| Nick Miles/Toomas Kull |
Cabinet Privé de Conseils s.a.
Phone: +41 22 321 45 40
| In the US |
The Communications Strategy Group Inc.
Phone: +1 781 631 3117